Sanofi to shutter ex-Kymab R&D facility in the UK

Sanofi is clos­ing an ex-Kymab re­search and de­vel­op­ment site in Cam­bridge, UK, which could see job loss­es for 90 staffers, a com­pa­ny spokesper­son told End­points News. 

“Up­on care­ful re­view of our R&D glob­al foot­print, we are propos­ing to end re­search op­er­a­tions in Cam­bridge, UK, a site which joined our com­pa­ny through ac­qui­si­tion in 2021,” the spokesper­son said in an email. Sanofi bought mon­o­clon­al an­ti­body de­vel­op­er Kymab for $1.45 bil­lion in April 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.